Clonal Hematopoiesis and Outcomes After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with AML, Myeloma, and Lymphoma
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26168021 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Corinne Natalie Schmid und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Inselspital, University Hospital of Bern, 3010 Bern, Switzerland. Hauptthemen laut MEDLINE: Multiple Myeloma, Clonal Hematopoiesis, Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Autologous stem cell transplantation (ASCT) after high-dose chemo-therapy (HDCT) is an option of consolidation therapy in patients with AML, lymphoma, or myeloma. Clonal hematopoiesis (CH) is a premalignant state, associated with an increased risk of hematological cancer. The incidence of CH in patients with AML, myeloma, and lymphoma and its effect on the outcome after HDCT/ASCT remain poorly studied. Here we screened 142 patients treated with HDCT/ASCT between 2002 and 2021 at Bern University Hospital for somatic gene mutations in ASXL1, DNMT3A, JAK2, TET2, and TP53. CH-associated somatic gene mutations were detected in 14/31 AML patients (45%), 13/64 myeloma patients (20%), and 9/47 lymphoma patients (19%). Clinical characteristics, treatment modalities, and responses to treatment were similar in patients with and without CH. Patients with CH-associated gene mutations had higher relapse rates and reduced progression free survival, most evident in lymphoma patients (p = 0.007). Overall survival tended to be shorter in lymphoma patients with CH-associated mutations (p = 0.078), whereas this was not observed in AML and myeloma patients. Survival in lymphoma patients with CH was inferior, which may have an impact on post-transplant surveillance strategies in the future. In contrast, survival outcomes were not associated significantly with CH in AML and myeloma patients in our study. Longer follow-ups and larger cohorts will be needed to validate our observations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Inselspital, University Hospital of Bern, 3010 Bern, Switzerland.
- Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
- Department for BioMedical Research, University of Bern, 3010 Bern, Switzerland.
ORCID-Profile: Ulrike Bacher, Katja Seipel, Naomi Porret, Gertrud Wiedemann, Michael Daskalakis, Thomas Pabst
Zitieren
APA
Schmid, C. N., Sponagel, K., Bacher, U., Seipel, K., Porret, N., Wiedemann, G., Hoffmann, M., Daskalakis, M., & Pabst, T. (2025). Clonal Hematopoiesis and Outcomes After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with AML, Myeloma, and Lymphoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26168021
Vancouver
Schmid CN, Sponagel K, Bacher U, Seipel K, Porret N, Wiedemann G, et al. Clonal Hematopoiesis and Outcomes After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with AML, Myeloma, and Lymphoma. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26168021
BibTeX
@article{Schmid2025,
author = {Schmid, Corinne Natalie and Sponagel, Katharina and Bacher, Ulrike and Seipel, Katja and Porret, Naomi and Wiedemann, Gertrud and Hoffmann, Michèle and Daskalakis, Michael and Pabst, Thomas},
title = {Clonal Hematopoiesis and Outcomes After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with AML, Myeloma, and Lymphoma},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26168021}
}
EUVIMED